… in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of …
A common benchmark to assess model development in multiple sclerosis is also currently …

… This multicentric study was conducted at five Neurorehabilitation departments of French
university hospitals. The procedure was approved by local ethic committee and patients …

… In conclusion, this large multicentre study suggests that early brain atrophy rates are
related to subsequent long term disability in MS, and that atrophy and lesion volumes have a …

… We conducted a national descriptive retrospective multicentre study on a case series of
patients aged >70 years at the time of VLO-IDE. Patients were recruited from a national call on …

… as a therapeutic option in multiple sclerosis (MS) and has been … multicentre, double-blind,
placebo-controlled study of two parallel-treatment groups of outpatients with SP-MS. The study …

… which has been associated with risk of multiple sclerosis. Therefore, targeting of these cells
might disrupt processes in multiple sclerosis pathogenesis. Studies of rituximab—a chimeric …

… international observational study, we obtained … multiple sclerosis as part of routine clinical
care. We identified adult patients (aged ≥18 years) with relapsing-remitting multiple sclerosis, …

… Multicentre, hospital-based cross-sectional study. An adapted version of the Brief Insomnia
Questionnaire was applied to a consecutively recruited MS population. The influence of …

… (GA; Copaxone†, TEVA Pharmaceutical Industries Ltd., Israel) is an immunomodulating
drug currently approved for the treatment of relapsingÁremitting multiple sclerosis (RRMS) [1]. …

… Treatment with the highest BG00012 dose studied reduced by 69% the mean number of …
in this study confirms results of a pilot study of ten patients with multiple sclerosis receiving oral …